Brief: Transgene, BioInvent Report Positive Phase Ia Data On Oncolytic Virus BT-001 In Solid Tumours

BioInvent International AB

25/05/2023 06:43

May 25 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE AND BIOINVENT REPORT POSITIVE PHASE IA DATA ON
ONCOLYTIC VIRUS BT-001 IN SOLID TUMORS
    * TREATMENT OF ALL PHASE IA COHORTS IN MONOTHERAPY COMPLETED
WITH
NO SAFETY CONCERNS
    * STABILIZATION OF INJECTED LESIONS IN 11/18 PATIENTS
    * BASED ON THESE RESULTS, INDEPENDENT SAFETY REVIEW
COMMITTEE
(SRC) HAS NOW APPROVED INITIATION OF COMBINATION PART OF TRIAL
WITH PEMBROLIZUMAB
    * FIRST PATIENT IN THIS PHASE I PART B IS EXPECTED TO BE
ENROLLED
IN H2 2023
    * INDEPENDENT SAFETY REVIEW COMMITTEE HAS APPROVED
INITIATION OF
COMBINATION TRIAL WITH PEMBROLIZUM

Source text for Eikon:  ID:nBw4v76m5a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))